HBM Healthcare Investments publishes net asset value per share (NAV) of CHF 248.10 as at 31 March 2024 and quarterly profit of CHF 156 million
Source: EQS
Positive currency effects accounted for around two thirds of the quarterly performance. Following a marked appreciation in the first nine months of the financial year, the Swiss franc weakened again significantly in the quarter under review. Listed investments also made a positive contribution to the result, while value adjustments at private companies had a slightly negative impact on overall performance.
Balanced result for the 2023/2024 financial year A balanced result was achieved for the 12 months of the 2023/2024 financial year. While the net asset value per share (NAV) rose by 0.3 per cent, a small annual loss of around Public companies contributed +5.7 per cent to the positive annual performance of +0.3 per cent. This was despite the renewed disappointing stock price performance of Cathay Biotech, the largest listed investment in the portfolio. Private companies and funds as well as negative currency effects had a adverse impact on performance in the financial year of -3.2 per cent and -2.5 per cent respectively. Of the net assets of These figures are the preliminary and unaudited results based on the current status of the financial closing process. The definitive annual result will be published on Wednesday, Contact News Source: End of Inside Information |
Language: | English |
Company: | |
Bundesplatz 1 | |
6300 |
|
Phone: | +41438887171 |
Fax: | +41438887172 |
E-mail: | info@hbmhealthcare.com |
Internet: | https://www.hbmhealthcare.com |
ISIN: | CH0012627250 |
Valor: | 1262725 |
Listed: | |
EQS News ID: | 1871773 |
End of Announcement |
|
1871773 02-Apr-